Skip to content

Biohaven BHVN Investment Proceeds

Investment Proceeds at other companies

Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$58.32M-9.7%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$170.6M-43.5%
uniQure logo
uniQureQURE
$98.7M+16.1%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$156.69M+38.4%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$133.15M-4.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$35M-74.5%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's investment proceeds?
Biohaven (BHVN) reported investment proceeds of $35M in Q1 2026.
How has Biohaven's investment proceeds changed year-over-year?
Biohaven's investment proceeds decreased by 83.3% year-over-year, from $210M to $35M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.